AN2 Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

ANTX$4.000.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Six Months EndedJune 30,
	2025	2024
Cash flows used in operating activities
Net loss	$(17,111)	$(31,052)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	4,045	4,656
Net accretion of discount on investments	(742)	(1,981)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,160)	314
Accounts payable	(1,204)	(791)
Accrued compensation	(477)	(2,178)
Accrued liabilities	(1,500)	(838)
Other current liabilities	(74)	(107)
Net cash used in operating activities	(18,223)	(31,977)
Cash flows from investing activities
Purchases of investments	(33,973)	(12,590)
Maturities of investments	49,000	55,340
Net cash provided by investing activities	15,027	42,750
Cash flows from financing activities
Proceeds from issuance of common stock under the ESPP	38	124
Proceeds from exercise of stock options	27	225
Net cash provided by financing activities	65	349
Net (decrease) increase in cash and cash equivalents	(3,131)	11,122
Cash and cash equivalents at the beginning of the period	21,351	15,647
Cash and cash equivalents at the end of the period	$18,220	$26,769

AN2 Therapeutics, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.